Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Anaesthesia medical workforce in New Zealand.

King SY.

Anaesth Intensive Care. 2006 Apr;34(2):261-5.

2.

New Zealand anaesthesia trainees and implications for the future workforce.

King SY, McGeorge AD.

Anaesth Intensive Care. 2005 Oct;33(5):651-5.

3.

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Burris HA 3rd, Raymond E, Awada A, Kuhn JG, O'Rourke TJ, Brentzel J, Lynch W, King SY, Brown TD, Von Hoff DD.

Invest New Drugs. 1998;16(1):19-27.

PMID:
9740540
4.

Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients.

Joshi AS, King SY, Zajac BA, Makowka L, Sher LS, Kahan BD, Menkis AH, Stiller CR, Schaefle B, Kornhauser DM.

J Clin Pharmacol. 1997 Dec;37(12):1121-8.

PMID:
9506007
5.

Dose-dependent pharmacokinetics of warfarin in healthy volunteers.

King SY, Joslin MA, Raudibaugh K, Pieniaszek HJ Jr, Benedek IH.

Pharm Res. 1995 Dec;12(12):1874-7.

PMID:
8786959
6.

Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers.

Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM.

J Clin Pharmacol. 1995 Dec;35(12):1181-6.

PMID:
8750369
7.

Simultaneous quantification of an anti-inflammatory compound (DuP 697) and a potential metabolite (X6882) in human plasma and urine by high-performance liquid chromatography.

Joshi AS, Raghavan N, Williams RM, Takahashi K, Shingu H, King SY.

J Chromatogr B Biomed Appl. 1994 Oct 3;660(1):143-50.

PMID:
7858707
8.

Plasma protein binding of highly bound drugs: implications of radiochemical impurities.

Joshi AS, Pieniaszek HJ Jr, Quon CY, King SY.

J Pharm Sci. 1994 Aug;83(8):1187-8. No abstract available.

PMID:
7983608
9.

Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.

King SY, Agra AM, Shen HS, Chi CL, Adams DB, Currie VE, Bertino JR, Pieniaszek HJ Jr, Quon CY.

Cancer Chemother Pharmacol. 1994;35(2):101-8.

PMID:
7987984
10.

ELISA determination and preliminary pharmacokinetics of modified human rIL-1 beta in dogs.

Gray JE, Peterman V, Newton R, King SY, Pieniaszek HJ Jr.

Res Commun Chem Pathol Pharmacol. 1993 Aug;81(2):233-41.

PMID:
8210701
11.

Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Benedek IH, King SY, Powell RJ, Agra AM, Schary WL, Pieniaszek HJ Jr.

J Clin Pharmacol. 1992 Jun;32(6):558-63.

PMID:
1634644
12.
13.

Effects of multiple doses of moricizine hydrochloride on its pharmacokinetics and hepatic microsomal enzymes in rats.

King SY, Powel RJ, Wong YN, Davidson AF, Vincent DR, Quon CY, Pieniaszek HJ Jr.

Res Commun Chem Pathol Pharmacol. 1992 Mar;75(3):259-74.

PMID:
1509197
14.

Lidocaine for the prevention of pain due to injection of propofol.

King SY, Davis FM, Wells JE, Murchison DJ, Pryor PJ.

Anesth Analg. 1992 Feb;74(2):246-9.

PMID:
1731545
15.

Self-association and solubility behaviors of a novel anticancer agent, brequinar sodium.

King SY, Basista AM, Torosian G.

J Pharm Sci. 1989 Feb;78(2):95-100.

PMID:
2715943
16.

Hospital managers' self-reported difficulties with sharing decision-making power with subordinates: six case studies.

King SY.

J Healthc Educ Train. 1987 Summer;2(2):22-7. No abstract available.

PMID:
10287478
17.
19.

Statistical prediction of drug stability based on nonlinear parameter estimation.

King SY, Kung MS, Fung HL.

J Pharm Sci. 1984 May;73(5):657-62.

PMID:
6737241
21.

Active treatment of children with end-stage renal failure.

King SY, Buttimore A, Lynn KL, Bailey RR.

N Z Med J. 1982 Nov 10;95(719):763-6.

PMID:
6755320

Supplemental Content

Support Center